Canaccord Genuity Maintains Buy on Thorne HealthTech, Raises Price Target to $7
Portfolio Pulse from jenniferd'souza@benzinga.com
Canaccord Genuity analyst Susan Anderson maintains a 'Buy' rating on Thorne HealthTech (NASDAQ:THRN) and raises the price target from $6 to $7.
August 11, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Thorne HealthTech's price target has been raised from $6 to $7 by Canaccord Genuity, which maintains a 'Buy' rating on the stock.
The news directly pertains to Thorne HealthTech. The raised price target and maintained 'Buy' rating by Canaccord Genuity is a positive signal, which could lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100